All In Biotech

Drug Trial Radar · NCT07032038

First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant

First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 2027

Primary completion

May 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Rinri TherapeuticsIndustry
Sponsor type
Industry
Collaborators
King's College London
First posted
Jun 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rinri Therapeutics is conducting a clinical trial of a new cell therapy called Rincell-1. Rincell-1 is being developed to treat adults with neural hearing loss, either age related hearing loss or auditory neuropathy, who also meet criteria for a cochlear implant. The goals of this study are: * To learn about the safety profile of Rincell-1, the procedure used to inject it and the medications given to promote the growth of the cells * To evaluate how well Rincell-1 works by measuring changes in the function of auditory neurons. * To understand if Rincell-1 can be easily and successfully given at the same time as cochlear implant surgery Participants will be randomly assigned to one of two groups: one group that receives a standard care cochlear implant, and the other that will receive an injection of Rincell-1 at the same time as their standard care cochlear implant. Researchers will compare the safety of Rincell-1 in combination with a cochlear implant to a cochlear implant on its own. Participants will take part in the trial for 52 weeks after CI surgery. During that time, they will have regular follow-ups and will take daily measurements at home of their hearing health.

Conditions

  • Sensorineural Hearing Loss
  • Presbyacusis
  • Auditory Neuropathy

Interventions

  • Otic neural progenitorsDrug

    Advanced Cell Therapy - tissue engineered product

  • cochlear implantationDevice

    cochlear implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of AEsTime frame: From baseline (at screening) to 52 weeks post-implantation

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Birmingham

    Birmingham, United Kingdom

  • Cambridge University Hospital

    Cambridge, United Kingdom

  • Guy's and St Thomas' Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.